Consequently, genetic testing is now advised for all patients newly diagnosed with non-small cell lung cancer (NSCLC), encompassing mutations in EGFR, anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS1), Rearranged during transfection (RET), B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E, and MET exon 14 skipping mutations. This evidence concerns the gene MARK2 and non-small cell lung carcinoma.